MaxQ Medical Raises $31.5 Million for Prostate Care Platform

Aug 20, 2026
MaxQ Medical raised $31.5 million in Series A funding to grow its team and advance clinical work on a transurethral imaging and therapy system for prostate care.

MaxQ Medical has closed a $31.5 million Series A financing to advance its prostate care platform, the company announced in a press release. The round was led by Atlantic Blue Ventures, S3 Ventures, and Olympus Innovation Ventures, with participation from existing investor Hillside Capital.

The company said the funds will be used to expand its team and move forward with its clinical program. MaxQ Medical is developing a transurethral system that combines advanced imaging with therapy in one procedure for prostate care.

The first planned indication is benign prostatic hyperplasia. MaxQ Medical also plans to expand the platform into focal therapy for prostate cancer and later into prostate diagnostics, including biopsy and tumor mapping.

We hope you enjoyed this article

Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.